canyon landscape

A phase 1, study of the safety and tolerability of single doses of ANK-700 in patients with relapsing-remitting Multiple Sclerosis.


The purpose of this study is to look at how safe it is to take single or multiple doses of the study drug in subjects with MS. The study will look at how long it takes the study drug to get into your bloodstream, the length of time it stays in your blood, and how it is broken down and processed by your body. This is called pharmacokinetics (PK).

The molecules, and cells in your blood are biomarkers and will be measured to see how your body is responding to the study drug.

The study will help determine how the study drug behaves inside the human body and how it is removed from the human body.

Open and enrolling subjects.
Phoenix, Arizona
Total Participants
Primary Sponsor
Anokion US, Inc.